Stem Cell Technologies And Applications Will Generate $15.8bn In 2019, A New Visiongain Analysis Predicts

13 September 2018
Pharma

A new visiongain report forecasts that the worldwide stem cell technological and applications market will generate revenues of $15.8bn in 2019. That forecast and others appear in Stem Cell Technologies and Applications Market Report 2016-2026: Hype vs Reality for That Transformative Technology with Vast R&D Pipeline and Expanding Use of HSCT and Cord Blood Banking, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Stem cells have been seen for many years as an upcoming and potentially transformative technology. In 2015, the market has yet to realise its great potential, but stem cell technologies remain on the cusp of significant market expansion. Factors such as the increasing use of hematopoietic stem cell transplantation (HSCT), the launch of current pipeline therapies and the expanding use of cord blood banking services and stem cell-based assays will stimulate this market over the next ten years.

“However the industry has many barriers to overcome. Current reimbursement and regulatory systems will need to be updated to adapt to the unique challenges posed by these non-traditional therapies. In addition, companies will have to attract the attention of Big Pharma, which sometimes remains wary of this exciting but potentially risky field.”

Visiongain’s updated analysis gives revenue forecasting to 2026 for the overall stem cell technologies and applications market. It also shows revenue predictions from 2015 to 2026 for the following five submarkets:

• Cancer treatment (oncology)
• Cardiovascular therapy
• CNS uses
• Other therapies
• Non-therapeutic applications.

The report also provides revenue forecasts to 2026 for six stem cell therapies:

• MSC-100-IV (Mesoblast)
• Hearticellgram-AMI (Pharmicell)
• CardioRel (Reliance Life Sciences)
• Osteocel Plus (NuVasive)
• Trinity Evolution and Elite (Orthofix)
• CARTISTEM (MEDIPOST).

That investigation shows interviews with the Human Stem Cells Institute (HSCI), Apceth, MEDIPOST, Harvard Stem Cells Institute and the Stem Cell Program at Boston’s Children’s Hospital. It also discusses research and development, reviewing the most promising advances. The study also discusses leading companies, assessing their activities and potentials.

Stem Cell Technologies and Applications Market Report 2016-2026 adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

Visiongain Publishes NGS-Based RNA Sequencing Market Report 2021-2031

The market is expected to be driven by key factors such as rising cancer prevalence, government funding support in genetic research and technological advancements taking place in the biological research field. In addition, the market is predicted to gain huge traction in the developing countries.

11 May 2021

Read

Visiongain Publishes Single-Use Bioreactors Market Report 2021-2031

Strong product portfolio in the market is one of the major factors accelerating the growth of the market as availability of variants in the single-use systems allows targeted users more options.

11 May 2021

Read

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever